Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of TMC125 in PI-naïve HIV-1 patients with prior NNRTI resistance
2004-001657-29Phase 2Completed
- Sponsor
- Tibotec
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of etravirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Tibotec. Primary endpoint: Proportion of subjects with HIV-1 RNA < 50 copies/mL at week 24. Started Feb 2005; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-001657-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001657-29.